Bottom line
IDEV vs GIIAX: the short answer
IDEV (iShares Core MSCI International Developed Markets ETF) and GIIAX (Nationwide International Index Fund) have nearly the same top holdings — their top 25 positions are about 86% the same by weight.
But IDEV is far broader, holding 2,337 positions to 693 for GIIAX, so beyond the top names it adds exposure GIIAX doesn't have.
IDEV is cheaper at 0.04% vs 0.69% — a difference of $65 a year per $10,000 invested.
Over five years, GIIAX returned +7.1% a year vs +5.0% for IDEV (reporting dates differ).
GIIAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
IDEV vs GIIAX side by side
| IDEV | GIIAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Nationwide |
| Category | International Stock | International Stock |
| Expense ratio | 0.04% | 0.69% |
| Annual cost per $10k | $4 | $69 |
| 10-yr cost on $10k (prospectus) | $51 | $1,457 |
| Max front load | None | 5.75% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +4.5% | +23.5% |
| 5-yr return (annualized) | +5.0% | +7.1% |
| 10-yr return (annualized) | — | +7.1% |
| Best quarter | +16.9% | +18.3% |
| Worst quarter | −24.0% | −22.8% |
| Net assets (fund) | $31.6B | $910.2M |
| Number of holdings | 2,337 | 693 |
| Portfolio turnover | 3% | 13% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IDEV | GIIAX | Difference |
|---|---|---|---|
| 2024 | +4.5% | +2.9% | +1.6% |
| 2023 | +17.3% | +17.0% | +0.3% |
| 2022 | −14.9% | −14.4% | −0.5% |
| 2021 | +12.7% | +10.6% | +2.1% |
| 2020 | +8.4% | +7.3% | +1.1% |
| 2019 | +23.4% | +21.5% | +1.8% |
| 2018 | −14.3% | −14.1% | −0.2% |
Source: Fund prospectus bar charts
Holdings overlap
19 of IDEV's top 25 holdings also appear in GIIAX's top 25.
| Holding | IDEV | GIIAX |
|---|---|---|
| ASML Holding N.V. | 2.19% | 2.86% |
| Hsbc Holdings Plc | 1.24% | 1.66% |
| Roche Holding AG | 1.05% | 1.38% |
| Novartis AG | 0.98% | 1.29% |
| Astrazeneca Plc | 0.88% | 1.16% |
| Nestle S.A. | 0.88% | 1.16% |
| Shell Plc | 0.88% | 1.16% |
| Mitsubishi UFJ Financial Group, Inc. | 0.82% | 1.08% |
| Commonwealth Bank Of Australia | 0.72% | 0.94% |
| Banco Santander, S.A. | 0.70% | 0.91% |
| Sap Se | 0.65% | 0.86% |
| Allianz SE | 0.65% | 0.85% |
| Schneider Electric Se | 0.63% | 0.83% |
| Totalenergies Se | 0.59% | 0.79% |
| UBS Group AG | 0.57% | 0.75% |
Source: SEC Form N-PORT
IDEV top 10
- ASML Holding N.V. — 2.19%
- Hsbc Holdings Plc — 1.24%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 1.16%
- Roche Holding AG — 1.05%
- Royal Bank Of Canada — 1.00%
- Novartis AG — 0.98%
- Astrazeneca Plc — 0.88%
- Nestle S.A. — 0.88%
- Shell Plc — 0.88%
- Siemens Aktiengesellschaft — 0.83%
GIIAX top 10
- ASML Holding NV — 2.86%
- HSBC Holdings plc — 1.66%
- Roche Holding AG — 1.38%
- Novartis AG — 1.29%
- AstraZeneca plc — 1.16%
- Shell plc — 1.16%
- Nestle SA — 1.16%
- Siemens AG — 1.09%
- Mitsubishi UFJ Financial Group, Inc. — 1.08%
- BHP Group Ltd. — 0.97%
FAQ
What is the difference between IDEV and GIIAX?
Which is cheaper, IDEV or GIIAX?
Should I own both IDEV and GIIAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.